ReferenceID 4368
Myricetin ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β signaling via targeting HSP90β
Biochem Pharmacol
Idiopathic pulmonary fibrosis is a progressive-fibrosing lung disease with high mortality and limited therapy, which characterized by myofibroblasts proliferation and extracellular matrix deposition. Myricetin, a natural
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 4368
- Evidence Id
- 20958
- Core Evidence Id
- 20958
- Source Reference Id
- 2002
- Herb2 Reference Id
- HBREF002799
- Subject Paper Key
- HBIN007081_32535102
- Pubmed Id
- 32535102
- Doi
- 10.1016/j.bcp.2020.114097
- Paper Title
- Myricetin ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β signaling via targeting HSP90β
- Paper Abstract
- Idiopathic pulmonary fibrosis is a progressive-fibrosing lung disease with high mortality and limited therapy, which characterized by myofibroblasts proliferation and extracellular matrix deposition. Myricetin, a natural flavonoid, has been shown to possess a variety of biological characteristics including anti-inflammatory and anti-tumor. In this study we explored the potential effect and mechanisms of myricetin on pulmonary fibrosis in vivo and vitro. The in vivo studies showed that myricetin effectively alleviated bleomycin (BLM)-induced pulmonary fibrosis. KEGG analysis of RNA-seq data indicated that myricetin could regulate the transforming growth factor (TGF)-beta signaling pathway. In vitro studies indicated that myricetin could dose-dependently suppress TGF-beta1/Smad signaling and attenuate TGF-beta1-induced fibroblast activation and epithelial-mesenchymal transition (EMT). Molecular docking indicated that heat shock protein (HSP) 90beta may be a potential target of myricetin, and MST assay demonstrated that the dissociation constant (Kd) of myricetin and HSP90beta was 331.59 nM. We demonstrated that myricetin interfered with the binding of HSP90beta and TGF-beta receptor II and impeded fibroblast activation and EMT. In conclusion, myricetin impedes TGF-beta1-induced lung fibroblast activation and EMT via targeting HSP90beta and attenuates BLM-induced pulmonary fibrosis in mice.
- Journal
- Biochem Pharmacol
- Publish Year
- 2020
- Experiment Subject
- mouse
- Experiment Type
- Animal & Cell Experiment
- Phenotype Related
- Idiopathic Pulmonary Fibrosis; Progressive-fibrosing Lung Disease; Pulmonary Fibrosis
- Paper Title Cn
- Paper Title En
- Myricetin ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β signaling via targeting HSP90β
- Bilingual Status
- semi_complete